SG11201810779PA - Method for screening antibody using patient-derived tumor spheroids - Google Patents

Method for screening antibody using patient-derived tumor spheroids

Info

Publication number
SG11201810779PA
SG11201810779PA SG11201810779PA SG11201810779PA SG11201810779PA SG 11201810779P A SG11201810779P A SG 11201810779PA SG 11201810779P A SG11201810779P A SG 11201810779PA SG 11201810779P A SG11201810779P A SG 11201810779PA SG 11201810779P A SG11201810779P A SG 11201810779PA
Authority
SG
Singapore
Prior art keywords
patient
derived tumor
tumor spheroids
screening antibody
antigen
Prior art date
Application number
SG11201810779PA
Inventor
Do-Hyun Nam
Original Assignee
Samsung Life Public Welfare Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samsung Life Public Welfare Foundation filed Critical Samsung Life Public Welfare Foundation
Priority claimed from PCT/KR2017/005766 external-priority patent/WO2017209553A2/en
Publication of SG11201810779PA publication Critical patent/SG11201810779PA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)

Abstract

The present disclosure relates to a method of screening an antibody or an antigen-binding fragment thereof by use of patient-derived tumor spheroids, and more particularly to a method of screening an antibody or an antigen-binding fragment thereof, which binds specifically to an antigen, by use of patient-derived tumor spheroids containing the antigen. - 66 -
SG11201810779PA 2016-06-03 2017-06-02 Method for screening antibody using patient-derived tumor spheroids SG11201810779PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160069355 2016-06-03
KR1020170069140A KR101993892B1 (en) 2016-06-03 2017-06-02 Method of Screening Antibody Using Patient Derived Cell
PCT/KR2017/005766 WO2017209553A2 (en) 2016-06-03 2017-06-02 Method for screening antibody using patient-derived cells

Publications (1)

Publication Number Publication Date
SG11201810779PA true SG11201810779PA (en) 2019-01-30

Family

ID=60944355

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810779PA SG11201810779PA (en) 2016-06-03 2017-06-02 Method for screening antibody using patient-derived tumor spheroids

Country Status (8)

Country Link
US (1) US11199536B2 (en)
EP (1) EP3480598A4 (en)
JP (2) JP6895460B2 (en)
KR (1) KR101993892B1 (en)
CN (1) CN109416364B (en)
AU (1) AU2017273169B2 (en)
CA (1) CA3026236C (en)
SG (1) SG11201810779PA (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023009392A (en) * 2021-02-10 2023-11-09 Shanghai Jemincare Pharmaceutical Co Ltd Anti-vegf antibody and use thereof.
WO2024091058A1 (en) * 2022-10-28 2024-05-02 주식회사 와이바이오로직스 Cell panning method

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3785186T2 (en) 1986-09-02 1993-07-15 Enzon Lab Inc BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN.
DE3852304T3 (en) 1987-03-02 1999-07-01 Enzon Lab Inc Organism as carrier for "Single Chain Antibody Domain (SCAD)".
EP0305500B1 (en) 1987-03-20 1994-11-09 Creative Biomolecules, Inc. Process for the purification of recombinant polypeptides
AU601273B2 (en) 1987-03-20 1990-09-06 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
DE3856559T2 (en) 1987-05-21 2004-04-29 Micromet Ag Multifunctional proteins with predetermined objectives
US5622699A (en) 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
DE69637395T2 (en) * 1995-09-11 2008-12-18 La Jolla Cancer Research Foundation, La Jolla Molecules that are in vivo in selected organs or tissues
US6576239B1 (en) * 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
DE69819927D1 (en) 1997-09-05 2003-12-24 Sun Microsystems Inc TABLE OF CONSIDERATION AND METHOD OF DATA STORAGE THEREIN
US6794128B2 (en) * 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
CN1408874A (en) * 2001-09-25 2003-04-09 韩泽广 Procaryotic cell in vivo antibody library construction screening and optimizing of antibody and use
US7306925B2 (en) 2001-11-09 2007-12-11 Vanderbilt University Phage antibodies to radiation-inducible neoantigens
US20050009110A1 (en) * 2003-07-08 2005-01-13 Xiao-Jia Chang Methods of producing antibodies for diagnostics and therapeutics
CN1224630C (en) * 2003-12-19 2005-10-26 复旦大学附属中山医院 Targetted polypeptide for specificity of liver cancer blood vessel
UA96139C2 (en) 2005-11-08 2011-10-10 Дженентек, Інк. Anti-neuropilin-1 (nrp1) antibody
EP2445536B1 (en) 2009-06-22 2016-06-08 Burnham Institute for Medical Research Methods and compositions using peptides and proteins with c-terminal elements
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
EP2591002A2 (en) * 2010-07-07 2013-05-15 Tubitak Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (vegfr- 2 /kdr)
KR101492436B1 (en) * 2012-06-21 2015-02-10 사회복지법인 삼성생명공익재단 Patient Specific Animal model for Glioblastoma and Uses thereof
KR101911438B1 (en) * 2012-10-31 2018-10-24 삼성전자주식회사 Bispecific antigen binding protein complex and preparation methods of bispecific antibodies
KR101327533B1 (en) * 2012-12-11 2013-11-08 사회복지법인 삼성생명공익재단 Novel screening system for personalized anti-cancer agents
JP2017502983A (en) * 2013-10-02 2017-01-26 スリ テクノロジーズ エルティーディー． Patient-specific immunotherapy to treat heterogeneous tumors
WO2015133882A1 (en) * 2014-03-07 2015-09-11 사회복지법인 삼성생명공익재단 Scfv antibody library, method for preparing same, and scfv antibody screening method using same

Also Published As

Publication number Publication date
AU2017273169B2 (en) 2020-07-30
KR20170137655A (en) 2017-12-13
CA3026236C (en) 2021-01-26
US20190227052A1 (en) 2019-07-25
JP2021097696A (en) 2021-07-01
EP3480598A2 (en) 2019-05-08
AU2017273169A1 (en) 2019-01-17
US11199536B2 (en) 2021-12-14
EP3480598A4 (en) 2020-01-22
CA3026236A1 (en) 2017-12-07
CN109416364B (en) 2022-04-12
CN109416364A (en) 2019-03-01
JP2019522966A (en) 2019-08-22
KR101993892B1 (en) 2019-06-28
JP6895460B2 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
MX2022002364A (en) Anti-pd-l1 antibodies.
PH12017502354A1 (en) Humanized and affinity matured antibodies to fcrh5 and methods of use
NZ766356A (en) Anti-pd-1 antibodies
EA201890302A1 (en) CHEMICAL ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF THEIR APPLICATION
PH12016501212B1 (en) Human anti-il-33 neutralizing monoclonal antibody
EP3294766C0 (en) Humanized antibody or fragment thereof specific for cd3
MX370818B (en) Anti-b7-h1 antibodies for treating tumors.
EA201792589A1 (en) ANTIBODIES AGAINST CD123 AND CONJUGATES OF INDICATED ANTIBODIES
EA201791139A1 (en) HETERODIMERNYE ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
EP3552665A3 (en) Antibodies
EA201791029A1 (en) ANTIBODIES AGAINST INTERLEUKIN-33 AND THEIR APPLICATION
PH12016500940A1 (en) HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
EP3702372A3 (en) Anti-cd40 human antibodies
MX2015013901A (en) Anti-il-4 antibodies and bispecific antibodies and uses thereof.
MX367661B (en) Novel anti-baff antibodies.
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
EA201990672A1 (en) ANTIBODIES SPECIFICALLY RELATING TO PD-1, AND THEIR FUNCTIONAL FRAGMENTS
MX2023006416A (en) Antibodies, uses & methods.
JOP20190246A1 (en) Monoclonal antibody to pd-l1
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2020012539A (en) Antibodies specific for cd3 and uses thereof.
EA201992315A1 (en) COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER
EA201891529A1 (en) COMPOSITIONS AND METHODS OF DETECTION AND TREATMENT OF OVARIAN CANCER
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
SG11201810779PA (en) Method for screening antibody using patient-derived tumor spheroids